Reassessing target antigens for adoptive T-cell therapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Adoptive T-cell therapy effectively targets malignant cells, offering durable responses in cancers like melanoma.
• A significant challenge is autoimmune toxicity due to T cells attacking healthy tissues expressing shared antigens.
• This limits the broader application of T-cell therapies.

Purpose of the Study:

• To reassess target antigen selection for adoptive T-cell therapy.
• To mitigate autoimmune toxicity by identifying tumor-specific antigens.
• To guide the development of safer and more effective T-cell treatments.

Main Methods:

• Review of T-cell therapy biology and clinical data.
• Analysis of tumor antigen expression profiles in malignant and healthy tissues.
• Evaluation of strategies to minimize T-cell receptor cross-reactivity.

Main Results:

• Many current tumor antigens are also present in essential healthy tissues, leading to autoimmune risks.
• Target antigens must be selectively expressed by tumors, not vital normal tissues.
• Strategies to reduce cross-reactivity can further mitigate adverse autoimmune events.

Conclusions:

• Circumspect target antigen selection is paramount for safe and effective adoptive T-cell therapy.
• Thoughtful preclinical and clinical studies are essential for advancing this treatment modality.
• Prioritizing tumor-specific antigens will improve the therapeutic index of T-cell therapies.